arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Acurx Pharmaceuticals, Inc.

ACXP
$1.56 ▲ +0.10 (+6.85%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
25 Visible periods
17 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Acurx Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.2M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -19.3%
FCF / Share $-0.52
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-1.68M
↑ +21.8%
FCF / Share Free cash flow per share
$-0.52
↑ +74.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
5
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 25 quarters